Molnupiravir N-1 CAS 2346620-55-9 COVID-19 High Quality

Short Description:

Product Name: Molnupiravir N-1 

CAS: 2346620-55-9

Appearance: White to Off-White Powder

Purity: ≥98.0%

Intermediate of Molnupiravir (CAS 2349386-89-4) in treatment of COVID-19

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Commercial Supply Molnupiravir and Related Intermediates with High Quality
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4

Chemical Properties:

Chemical Name Molnupiravir N-1
Synonyms ((3aR,4R,6R,6aR)-6-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate; Molnupiravir Intermediate; Molnupiravir Dimethyl Dioxol Impurity; Molnupiravir Impurity 11
CAS Number 2346620-55-9
CAT Number RF-PI310
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C16H23N3O7
Molecular Weight 369.37
Solubility Soluble in DMSO
Density 1.51±0.1 g/cm3
Shipping Temperature Ambient
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Powder
Loss on Drying ≤1.0%
Residue on Ignition ≤0.20%
Single Impurity ≤0.50%
Total Impurities ≤2.0%
Heavy Metals ≤20ppm
Purity ≥98.0% 
Test Standard Enterprise Standard
Usage Intermediate of Molnupiravir (CAS 2349386-89-4) COVID-19

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Molnupiravir N-1 (CAS 2346620-55-9), is the intermediate of Molnupiravir (CAS 2349386-89-4) in treatment of COVID-19. Molnupiravir (EIDD-2801) is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever. Molnupiravir (EIDD-2801) is efficiently hydrolyzed in vivo after absorption, resulting in detection of only free NHC in plasma. EIDD-2801 robustly reduces MERS-CoV infectious titers, viral RNA, and pathogenesis under both prophylactic and early therapeutic conditions. Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.

  • Write your message here and send it to us